Art

J-GLOBAL ID：201302222514348526   Reference number：13A0340647

Investigation of shortening infliximab infusion time in patients with rheumatoid arthritis

関節リウマチ患者におけるインフリキシマブ点滴投与時間短縮の検討

Author (9)： TSURU TOMOMI (相生会 ピーエスクリニック) ,  SUZAKI MIDORI (相生会 ピーエスクリニック) ,  KOBAYASHI YUMI (相生会 ピーエスクリニック) ,  SAKAMOTO AKEMI (相生会 ピーエスクリニック) ,  UCHINO AYUMI (九大 病院 免疫・膠原病・感染症内科) ,  NAKAGAWA MISATO (相生会 ピーエスクリニック) ,  ETO TAKASHI (相生会 ピーエスクリニック) ,  ISHIBASHI MOTOKI (相生会 ピーエスクリニック) ,  NAKAJIMA HITOSHI (福岡大 医 腎臓膠原病内科)
Material： 臨床医薬  (Journal of Clinical Therapeutics & Medicines)
Volume： 29  Issue： 1  Page： 45-49  Publication year： Jan. 31, 2013 
JST Material Number： Y0906A  ISSN： 0910-8211  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： *monoclonal antibody ,...
Semi thesaurus term： *rheumatoid arthritis ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=13A0340647&from=J-GLOBAL&jstjournalNo=Y0906A") }}

JST classification (4)： Clinical application of anti-inflammatory drugs  (GW15020E) ,  Clinical application of immunotherapeutic agents and blood preparations  (GW22020O) ,  Drug therapy(=pharmacotherapy)for musculoskeletal diseases  (GG05020D) ,  Treatment for immunologic diseases,allergic diseases.  (GD04030Y)

Reference (8)：

• 1)Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Tbder JS, Warner D, Quinn A,Keenan GE Schaible TF;PROMPT Study Group. Profiling Rernicade Onset with MTX in a Prospective Trial:Open label study to assess infliximab safety and timing of onset of clinical benefit among Patients with rheumatoid arthritis. J Rheumatol,29(4):667-677,2002.
• 2)Greenberg JD, Reed G, Decktor D, Harrold L, Furst D,Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM;CORRONA Investigators:Acomparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheurnatoid arthritis patients:results frorn the US CORRONA registry Ann Rheum Dis,71(7):1134-1142.2012.
• 3)van den Hout WB, Goekoop-Ruiterman YP, 'Allaart CE de Vries-Bouwstra JK, Hazes JM, Kerstens pJ, van Zeben D, Hulsmans HM, de Jonge-Bok JM, de Sonnaville PB, Dijkmans BA, Breedveld FC:Cost- utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheurn,61(3):291-299,2009.
• 4)Wong JB, Singh G, Kavanaugh A:Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med,113(5):400-408, 2002.
• 5)Kobelt G, J6nsson L, Ybung A, Eberhardt K:The cost-effectiveness of infliximab(Remicade)in the treatrnent of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study Rheumatology, 42(2):326-335,2003.

Terms in the title (5)： 関節リウマチ ,  患者 ,  インフリキシマブ ,  点滴投与 ,  時間短縮